Indications

Non-Hodgkin’s Lymphoma (NHL)

RIABNI^® (rituximab-arrx) is indicated for the treatment of adult patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
Chronic Lymphocytic Leukemia (CLL)

RIABNI^®, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.

Behind Riabni® A RITUXIMAB BIOSIMILAR WITH 1-WEEK STORAGE

Total storage vs. other
	RIABNI®¹
Storage time	UP TO 7 DAYS when diluted in 0.9% Sodium Chloride, USP

Protect diluted solution from light¹
Only administer RIABNI® as an intravenous (IV) infusion¹

*Diluted solutions are to be stored at 2°C to 8°C (36°F to 46°F).

1-WEEK storage MAY ALLOW FOR

REDUCED DRUG WASTE

IMPROVED PLANNING &
RESOURCE UTILIZATION

RIABNI® has an established Q-CODE: Q5123

RIABNI® is supplied as a clear to slightly opalescent, colorless to slightly yellow solution for IV infusion. There should not be particulates or discoloration in the single-dose vial.¹

RIABNI® solution is supplied as either:¹

100 mg/mL (10 mg/mL) single-dose vial
500 mg/mL (10 mg/mL) single-dose vial

Dilute to a final concentration 1 mg/mL to 4 mg/mL in an infusion bag containing either 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP. Diluted solutions should be refrigerated (2°C to 8°C).¹

Behind Riabni® A RITUXIMAB BIOSIMILAR WITH 1-WEEK STORAGE

1-WEEK storage MAY ALLOW FOR

IMPORTANT SAFETY INFORMATION AND INDICATIONS

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Warnings and Precautions

Infusion-Related reactions (IRR)

Severe Mucocutaneous Reactions

Hepatitis B Virus Reactivation

Progressive Multifocal Leukoencephalopathy (PML)

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Additional Important Safety Information

Adverse Reactions

Pregnancy and Nursing Mothers

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI® infusion and advise patients to read guide.

INDICATIONS

Non-Hodgkin’s Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)